[go: up one dir, main page]

MX2017011392A - P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion. - Google Patents

P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.

Info

Publication number
MX2017011392A
MX2017011392A MX2017011392A MX2017011392A MX2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A
Authority
MX
Mexico
Prior art keywords
crystal form
toluenesulfonate
preparation
kinase inhibitor
mek kinase
Prior art date
Application number
MX2017011392A
Other languages
English (en)
Other versions
MX382056B (es
Inventor
Wu Guaili
Gao Xiaohui
Bian Lin
JIA Junlei
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017011392A publication Critical patent/MX2017011392A/es
Publication of MX382056B publication Critical patent/MX382056B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un p-toluensulfonato para un inhibidor de MEK cinasa, y una forma de cristal del mismo y un método de preparación del mismo. De manera específica, se describe p-toluensulfonato de 2-((2-fluorine-4-yodofenil)amino)-1-metil-4-((6-metilpiridin-3-gr upo)oxigrupo)-6-carbonil-1,6-dihidropiridin-3-formamida (un compuesto representado por la fórmula (I)), y una forma de cristal I y un método de preparación del mismo. La forma de cristal I obtenida del compuesto representada por la fórmula (I) tiene buena estabilidad de forma de cristal y estabilidad química, y un solvente de cristalización usado tiene baja toxicidad y bajo residuo y puede usarse mejor en el tratamiento clínico. (ver Fórmula).
MX2017011392A 2015-03-27 2016-03-08 P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación. MX382056B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510141303 2015-03-27
PCT/CN2016/075853 WO2016155473A1 (zh) 2015-03-27 2016-03-08 一种mek激酶抑制剂的对甲苯磺酸盐、其结晶形式及制备方法

Publications (2)

Publication Number Publication Date
MX2017011392A true MX2017011392A (es) 2018-01-15
MX382056B MX382056B (es) 2025-03-13

Family

ID=57005438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011392A MX382056B (es) 2015-03-27 2016-03-08 P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación.

Country Status (12)

Country Link
US (2) US10118911B2 (es)
EP (1) EP3275866B1 (es)
JP (1) JP2018509407A (es)
KR (1) KR20170131506A (es)
CN (1) CN106795116B (es)
AU (1) AU2016239028B2 (es)
BR (1) BR112017018580A2 (es)
CA (1) CA2978796A1 (es)
MX (1) MX382056B (es)
RU (1) RU2704251C2 (es)
TW (1) TWI705060B (es)
WO (1) WO2016155473A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201818936A (zh) 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
TW201821408A (zh) * 2016-12-01 2018-06-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物的製備方法及其中間體
CN113423398A (zh) * 2019-01-29 2021-09-21 贝达药业股份有限公司 Mek抑制剂及其在医药上的应用
WO2021018112A1 (zh) * 2019-07-29 2021-02-04 江苏恒瑞医药股份有限公司 一种1，6-二氢吡啶-3-甲酰胺衍生物的制备方法
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
AU2023276599A1 (en) * 2022-05-25 2024-12-05 Imagenebio, Inc. Mek inhibitors and uses thereof
CN120441478A (zh) * 2024-02-07 2025-08-08 成都赜灵生物医药科技有限公司 一种六元内酰胺类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272290B (it) * 1994-06-20 1997-06-16 Avantgarde Spa Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US20110039819A1 (en) 2008-04-22 2011-02-17 Marion Hitchcock Substituted phenoxybenzamides
KR20110103968A (ko) * 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
CN102459188A (zh) * 2009-06-15 2012-05-16 凯美隆(北京)药业技术有限公司 新型6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
US20120238599A1 (en) * 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
WO2014204263A1 (en) * 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
US9914703B2 (en) * 2013-10-25 2018-03-13 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof

Also Published As

Publication number Publication date
BR112017018580A2 (pt) 2018-04-24
US20180370948A1 (en) 2018-12-27
TW201634459A (zh) 2016-10-01
CN106795116A (zh) 2017-05-31
CN106795116B (zh) 2019-11-01
RU2017134709A3 (es) 2019-07-17
JP2018509407A (ja) 2018-04-05
US10118911B2 (en) 2018-11-06
EP3275866B1 (en) 2019-12-04
WO2016155473A1 (zh) 2016-10-06
EP3275866A4 (en) 2018-08-15
RU2017134709A (ru) 2019-04-29
US20180118715A1 (en) 2018-05-03
AU2016239028A1 (en) 2017-09-14
AU2016239028B2 (en) 2019-09-19
KR20170131506A (ko) 2017-11-29
EP3275866A1 (en) 2018-01-31
RU2704251C2 (ru) 2019-10-25
MX382056B (es) 2025-03-13
TWI705060B (zh) 2020-09-21
CA2978796A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
PE20170300A1 (es) Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201790271A1 (ru) Ингибиторы гликозидазы
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
MX2017002206A (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
CL2017002813A1 (es) Proceso para preparar 4-amino-piridazinas
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2018010191A (es) Inhibidores de glucosidasa.
EA201790112A1 (ru) Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror)
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
MX375638B (es) Proceso para la fabricación de medicamentos.
AR104342A1 (es) Compuesto heterocíclico
EA201491276A1 (ru) Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
MX2017009696A (es) Formas cristalinas de c21h22cl2n4o2.
CL2012002286A1 (es) Procesos para preparar cde 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-(sustituidas) piperazin-1-il)carbonil]ciclopropil}benzamida; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion del intermediario.
EA201591498A1 (ru) Азетидинилоксифенилпирролидиновые соединения